莎普爱思(603168.SH)公告称，大股东陈德康因个人资金需求，计划自公告披露之日起15个交易日后的3 个月内，通过集中竞价和大宗交易方式减持不超过7,518,500股，即不超过公司总股本的2.00%。减持期 间为2025年9月25日至2025年12月24日。减持价格不低于公司首次公开发行股票的发行价。 ...

智通财经APP讯，莎普爱思(603168.SH)发布公告，陈德康先生因个人资金需求，计划自公告披露之日 起15个交易日后的3个月内，减持数量合计不超过751.85万股，即不超过公司总股本的2%。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new eye drop product aimed at treating presbyopia in adults [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Zhejiang Shapu Health Management Co., Ltd., has obtained the clinical trial approval notice for the drug, with the notice number 2025LP02246 [1] - The company plans to initiate clinical trials once conditions are met [1] Group 2: Financial Investment - As of the announcement date, the total research and development investment for the pilocarpine hydrochloride eye drops project amounts to approximately 6.4457 million RMB [1]

Core Viewpoint - The company, ShaPu AiSi (603168.SH), has received approval from the National Medical Products Administration for clinical trials of a new eye drop product aimed at treating presbyopia in adults [1] Group 1: Company Developments - ShaPu AiSi's wholly-owned subsidiary, Zhejiang ShaPu Health Management Co., Ltd., has obtained the "Drug Clinical Trial Approval Notice" for the drug, which is identified as hydrochloride pilocarpine eye drops [1] - The company plans to initiate clinical trials once conditions are met [1] - As of the announcement date, the total research and development investment for the hydrochloride pilocarpine eye drops project has reached approximately 6.4457 million RMB [1]

Core Points - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Sulfate Terbutaline Nebulization Solution from the National Medical Products Administration [1][4] - The approved drug is indicated for alleviating bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [2] - The total R&D investment for this drug has reached approximately 5.0111 million RMB [3] Drug Registration Details - Drug Name: Sulfate Terbutaline Nebulization Solution [1] - Dosage Form: Inhalation preparation [1] - Specification: 2ml: 5mg [1] - Registration Classification: Chemical drug category 4 [1] - Approval Number: National Drug Approval Code H20255228 [1] - License Holder: Zhejiang Shapuaisi Pharmaceutical Co., Ltd. [1] - Approval Conclusion: The drug meets the registration requirements as per the Drug Administration Law of the People's Republic of China [1] Impact on the Company - The approval of the Sulfate Terbutaline Nebulization Solution will enrich the company's product portfolio and optimize its product layout [4] - Future production and sales of the drug are subject to uncertainties influenced by pharmaceutical industry policies, bidding procurement, and market environment changes [4]

Group 1 - The company has received the Drug Registration Certificate for Sulbutamol Nebulization Solution, which is classified as a chemical drug of category 4 [1][2] - The drug is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1] - The total R&D investment for this drug has reached approximately 5.0111 million RMB [2] Group 2 - The approval of the drug will enrich the company's product portfolio and optimize its product layout [2] - Future production and sales of the drug are subject to uncertainties due to factors such as pharmaceutical industry policies, bidding procurement, and market environment changes [2]

Core Viewpoint - The company, Shapuaisi, has received the drug registration certificate for Sulfate Terbutaline aerosol inhalation solution from the National Medical Products Administration [2] Group 1 - The announcement was made on the evening of September 2 [2] - The drug is intended for aerosol inhalation use [2]

Core Viewpoint - The company Shapuaisi (603168.SH) has received a drug registration certificate from the National Medical Products Administration for its nebulized solution of Terbutaline Sulfate, which is intended to alleviate bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1] Company Summary - Shapuaisi has been granted a drug registration certificate (Certificate No. 2025S02611) for its nebulized solution of Terbutaline Sulfate [1] - The approved product is designed to provide relief for patients suffering from bronchial asthma, chronic bronchitis, emphysema, and other related pulmonary conditions [1]

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for a nebulized solution of Terbutaline Sulfate, which is intended to alleviate bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1] Company Summary - The approved product is a nebulized solution of Terbutaline Sulfate, which targets respiratory conditions [1] - The cumulative R&D investment for this drug has reached approximately 5.0111 million RMB [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江莎普爱思药业股份有限公司（以下简称 "公司"、"莎普爱思"）收 到国家药品监督管理局核发的硫酸特布他林雾化吸入用溶液的《药品注册证书》（证书 编号：2025S02611），现将有关信息公告如下： 证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-048 浙江莎普爱思药业股份有限公司 关于获得硫酸特布他林雾化吸入用溶液 《药品注册证书》的公告 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药 品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他情况 本次获批的硫酸特布他林雾化吸入用溶液，可缓解支气管哮喘、慢性支气管炎、肺 气肿及其它肺部疾病所合并的支气管痉挛。 一、《药品注册证书》主要内容 药品名称：硫酸特布他林雾化吸入用溶液 剂型：吸入制剂 规格：2ml：5mg 注册分类：化学药品4类 药品批准文号：国药准字H20255228 上市许可持有人：浙江莎普爱思药业股份有限公司 截至本公告披露日，公司针对该药品的累计研发投入约 ...